MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Catalyst Biosciences Total Shareholders Equity 2011-2026 | CBIO
Annual Total Shareholders Equity Catalyst Biosciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -15.8 M | 42.5 M | 41.1 M | 76.1 M | 68.3 M | 120 M | 30.8 M | 16.1 M | 31.4 M | -109 M | -103 M | -93.3 M | 174 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 174 M | -109 M | 21.5 M |
Quarterly Total Shareholders Equity Catalyst Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102 M | 92 M | 68.1 M | 63.3 M | 98.5 M | 93.3 M | 88.8 M | -15.8 M | 85.3 M | 77.5 M | 77.3 M | -21.7 M | 29.4 M | 79.1 M | 27.1 M | 41.1 M | 60.7 M | 85.2 M | 104 M | 76.1 M | 76.1 M | 76.1 M | 76.1 M | 68.3 M | 68.3 M | 68.3 M | 68.3 M | 120 M | 120 M | 120 M | 120 M | 30.8 M | 30.8 M | 30.8 M | 30.8 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 31.4 M | 31.4 M | 31.4 M | 31.4 M | -109 M | -109 M | 109 M | 109 M | -103 M | 135 M | 135 M | 135 M | -93.3 M | 176 M | 176 M | 176 M | 174 M | 174 M | 174 M | 174 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 176 M | -109 M | 68.4 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biogen
BIIB
|
16.7 B | $ 173.17 | 0.92 % | $ 25.2 B |  USA |
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
50.5 M | $ 2.4 | -3.61 % | $ 135 M |  China |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
BioNTech SE
BNTX
|
1.37 B | $ 117.62 | 1.41 % | $ 27.2 B | Germany |
 |
Aptorum Group Limited
APM
|
21.1 M | $ 0.98 | 1.35 % | $ 5.34 M | China |
 |
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.67 | 3.38 % | $ 8.83 B |  Australia |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-93.1 M | $ 1.77 | -2.75 % | $ 4.49 M | USA |
 |
BioLineRx Ltd.
BLRX
|
22 M | $ 3.12 | 0.59 % | $ 908 M |  Israel |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Cellectis S.A.
CLLS
|
309 M | $ 4.13 | -6.56 % | $ 116 M | France |
 |
Ascendis Pharma A/S
ASND
|
884 M | $ 233.49 | -0.81 % | $ 5 B |  Danmark |
 |
Burford Capital Limited
BUR
|
1.7 B | $ 9.71 | -0.46 % | $ 1.57 B | Britain |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
466 M | $ 67.41 | 0.54 % | $ 9.02 B | USA |
 |
Compugen Ltd.
CGEN
|
54.9 M | $ 2.04 | -2.39 % | $ 183 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.44 M | $ 4.36 | -2.46 % | $ 9.49 B | Israel |
 |
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
518 M | - | - | $ 1.01 B | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
39.5 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
732 M | $ 26.57 | 2.51 % | $ 1.29 B | USA |
 |
Coherus BioSciences
CHRS
|
-193 M | $ 2.26 | 9.7 % | $ 213 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
-109 M | $ 13.59 | 1.46 % | $ 4.2 B | USA |
 |
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Aptose Biosciences
APTO
|
-4.54 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | USA |
 |
Athira Pharma
ATHA
|
44.8 M | - | - | $ 269 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Celldex Therapeutics
CLDX
|
747 M | $ 26.72 | 3.09 % | $ 1.72 M | USA |
 |
AVROBIO
AVRO
|
94.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
19 M | $ 2.75 | 1.85 % | $ 17.3 M | USA |
 |
AstraZeneca PLC
AZN
|
15.6 B | $ 94.24 | 1.38 % | $ 96.9 B | Britain |
 |
Arena Pharmaceuticals
ARNA
|
673 M | - | -6.81 % | $ 3.04 B | USA |
 |
Brickell Biotech
BBI
|
9.93 M | - | -5.38 % | $ 6.06 M | USA |